Oncology

The second article in a two-part series examines oncology drug approvals and late-breaking FDA actions.

Connecticut man achieves remission via Revlimid therapy while bolstered by the love of his wife and children.

Researchers find the amplification and mutation of human epidermal growth factor receptor 2 should be treated separately.

Blincyto treats adult patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor ALL.

Blincyto treats adult patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor ALL.

Emend found to provide a greater delay in nausea and vomiting from cancer treatment than other medicines.

Emend found to provide a greater delay in nausea and vomiting from cancer treatment than other medicines.

Testimony from public speakers at FDA advisory committee meetings under increased scrutiny.

Annual per patient cost for pancreatic therapies and medications found to create significant financial burden.

Testimony from public speakers at FDA advisory committee meetings under increased scrutiny.

Use of 3-D technology explains how cancerous cells recruit healthy cells.

Nearly 15% of colorectal cancers diagnosed before the recommended screening age of 50.

Top news of the week in oncology drug development.

Food additive induces cells to make protective antioxidants and make repairs.

Precision medicine and immune oncology transform cancer treatment.

Optogenetics technique harnesses immune system to reduce tumor size and metastasis.

Treatment delivers miRNA to late-stage liver cancer tumors with low toxicity.

Study estimates cancer will cause an economic burden of $8.3 trillion worldwide from 2011 to 2030.

Women diagnosed with malignant melanoma during pregnancy or within 1 year of giving birth were 5.1 times as likely to die.

Improved colon cancer survival rate attributed to more aggressive treatment.

Afatinib showed significant improvement in progression-free survival and objective response rate in non-small cell lung cancer patients.

Dinutuximab is the first immunotherapy approved for the treatment of a pediatric cancer.

Afatinib showed significant improvement in progression-free survival and objective response rate in non-small cell lung cancer patients.

Researchers seek to determine the ideal duration between radiation treatment and the actual surgical removal of cancerous cells.

Nisin shows promise in killing cancer and deadly bacteria resistant to antibiotics.

Annatto is commonly found in the seeds of the achiote fruit.

Newly identified biomarker may help determine whether patients will need chemotherapy post-surgery.

Adcetris is currently the only approved molecular-targeted therapy for Hodgkins lymphoma.